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Mycobacterium avium subsp. paratuberculosis (MAP), the
causative agent of Johne disease in ruminants, has been
incriminated as the cause of Crohn disease in humans. We
report the first case of human infection with MAP in a patient
with HIV; infection was confirmed by obtaining isolates from
several different specimen types. 
pportunistic infections caused by various Mycobacterium
species are among the leading AIDS indicator diseases in
HIV-positive patients (1). Infections with nontuberculous
mycobacteria occur mainly in patients who have low CD4+
counts (<50 cells) or high virus counts (2); Mycobacterium
avium complex is the most important mycobacterial species.
M. avium complex includes the species M. avium and M. intra-
cellulare, with M. avium consisting of M. avium subsp. avium,
M. avium subsp. sylvaticum, and M. avium subsp. paratuber-
culosis (MAP). All these subspecies have identical 16S rRNA
gene and 16S to 23S transcribed spacer sequences, as well as
shared biochemical characteristics (3). However, MAP  is
dependent on mycobactin for its growth, whereas M. avium
grows well on different solid media.
MAP is the causative agent of Johne disease, a chronic
granulomatous ileitis occurring mainly in ruminants (4). MAP
has been incriminated as the cause of Crohn disease in humans
(5,6), although conflicting findings have been reported. How-
ever, culture-confirmed cases of MAP  in human specimens
remain rare (5,6).
Case Report
A 36-year-old HIV-positive man, who had been treated at
our hospital since 1995 for HIV, hepatitis C, and hemophilia,
had profuse diarrhea (6–8 episodes/day), fever as high as
39.9°C, and 10 kg of body weight loss in 5 weeks. Laboratory
findings included hemoglobin 9.6 g/dL, pseudocholinesterase
2,099 U/L, HIV-DNA virus count 500 copies/mL, CD4+ lym-
phocyte count 29 x 106/mL, and C-reactive protein 76 mg/L.
Stained colon tissue samples, bone marrow punch, and liver
biopsy showed abundant acid-fast bacilli. Endoscopic findings
on colonoscopy were multiple polypoid lesions approximately
5 mm in size in the transverse and sigmoid colon.
Microbiologic analyses included culture for mycobacteria
(liquid media: BACTEC 460TB or MGIT [Becton, Dickinson
and Company, Cockeysville, MD] and solid media produced in-
house, all media without supplementation of mycobactin) from
at least 21 specimens (blood, urine, sputum, biopsy, feces) over
a 3-year period. Of these, eight specimens (blood, feces, and
biopsy) were positive for mycobacteria in liquid media after 6 to
16 weeks of incubation. Subcultures remained negative on
Löwenstein-Jensen slants but after approximately 4 weeks
became positive on mycobactin-supplemented Middlebrook
slants with colorless dysgonic colonies. Microscopic examina-
tion of these colonies showed acid-fast bacilli (Figure 1). 
For species identification, AccuProbe assays (Gen-Probe,
San Diego, CA) for M. avium complex were performed on liq-
uid media, all yielding strong positive results. However,
repeated attempts to perform drug-susceptibility testing in the
liquid BACTEC 460TB system were unsuccessful because of
insufficient growth of the control. Since M. avium complex
usually grows very well, the primary identification was ques-
tionable. Thus, polymerase chain reaction (PCR) for the
amplification of a part of the mycobacterial gene coding for
the ribosomal 16S RNA and additional sequencing was per-
formed from two positive cultures (7). The resulting sequence
was compared with those stored in the International
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Figure 1. Ziehl-Neelsen–stained micrograph of Mycobacterium avium
subsp. paratuberculosis colonies growing on mycobactin-supple-
mented Middlebrook agar.DISPATCHES
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Nucleotide Sequence Database (8), showing the signature
sequence of M. avium/M. paratuberculosis, which is identi-
cal for both species and confirmed the AccuProbe results.
For further differentiation between M. avium and MAP, PCR
targeting the insertion sequence IS900 (primer: IS900-1: 5´-
TGTTCGGGGCCGTCGCTTAG; IS900-2: 5´-CGTTCCAGC
GCCGAAAGTAT), which is present only in MAP strains (9),
was done with the two most recent positive cultures. This
assay showed clearly positive results from the two cultures
tested and the MAP type strain, while the M. avium strains
remained negative (Figure 2). 
Because acid-fast bacilli were identified in biopsy speci-
mens, treatment was started with ethambutol, ciprofloxacin,
clarithromycin, and rifabutin. Initially, no clinical improve-
ment was observed, and the patient’s weight loss and daily
fever of 39C°–40°C continued. When ciprofloxacin was
replaced with levofloxacin, progression of the infection
appeared to stop. However, the patient died from cardiorespi-
ratory failure. 
Conclusions
We describe the case of an HIV-infected patient who had a
severe mycobacterial disorder thought to be caused by M.
avium complex. Because growth was insufficient for suscepti-
bility testing, the presence of MAP was assumed; however, the
assumption was made after 2 years, because of difficulties in
isolating MAP from human specimens (e.g., blood) in media
not thought to enable its growth. Finally, the demonstration of
the insertion sequence IS900, an assay not routinely performed
in human diagnostic laboratories like ours, confirmed this
hypothesis. 
MAP  isolated from human specimens has not yet been
demonstrated by routine techniques. Several studies have
reported the presence of MAP DNA in association with Crohn
disease, although culture confirmation remains rare in these
patients (5,6). 
In the case we describe, mycobacterial growth could be
detected in liquid media in 8 of 21 specimens, all confirmed as
M. avium complex/M. paratuberculosis. However, because of
the limited growth, we assume the presence of MAP even in
those specimens not tested by IS900 PCR. These results indi-
cate that MAP can grow to a limited extent in routine liquid
media without mycobactin supplementation, at least if present
in high amounts in the specimen.
Susceptibility testing of the isolated strains could not be
performed because of insufficient growth. Reports on suscepti-
bility testing of  MAP  are rare, yet data obtained by a
luciferase-based susceptibility assay (10) indicate susceptibil-
ity at least to clarithromycin and rifabutin, which were
included in therapy. However, the patient’s response to treat-
ment was not clearly positive and may have been hampered by
his general poor health. This report suggests a pathogenic role
of MAP for immunocompromised patients, raising the ques-
tion of whether this strain so far has not been detected because
of its limited growth, whether it has been misidentified as M.
avium, or whether its occurrence in infections is low. How-
ever, herd prevalence of bovine paratuberculosis has been
reported to range from 7% to 55% in Europe and to reach
approximately 40% in stocks of >300 animals in the United
States (4). Thus, consumption of inadequately pasteurized
dairy products may be a possible risk for infection, especially
for immunocompromised patients.
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